The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cell Line, 2002Development and Utilization of Dopaminergic Cell Lines for the Treatment of Parkinson's Disease
We have recently succeeded in differentiating adult human and animal bone marrow stromal stem cells (BMSCs) into neurons (nerve cells). A subpopulation of the neurons activates functions that are...
-
Cell Line, 2002Development & characterization of adult substantia nigra derived neural progenitor cells
There is growing evidence that certain areas of the adult central nervous system retain the capacity to generate new neurons from endogenous immature progenitor cells. Our preliminary results show...
-
Cell Line, 2002Establishing stable lines of human nigral dopaminergic progenitor cells
We intend to develop lines of clonal, stable and self-renewing human dopamine-producing neuronal progenitor cells. These will be derived from the part of the midbrain that gives rise to dopamine...
-
Fast Track, 2001Lentiviral Delivery of Neublastin to MPTP-Treated Pre-clinical models
Parkinson's disease (PD) results primarily from striatal dopamine (DA) insufficiency and degeneration of dopaminergic neurons within the substantia nigra pars compacta. The cause of PD still remains...
-
Fast Track, 2001Rapid Parkinson's Drug Screen Using Parkin Knockout Stem Cells
Autosomal recessive loss-of-function mutations in the parkin gene are the most common cause of familial Parkinson's disease (PD), which is characterized by selective loss of dopaminergic (DA) neurons...
-
Fast Track, 2001PET Neuroimaging Study of the Brain Serotonin Transporter in Parkinson's Disease: Relationship to Clinical Depression
Approximately 40% of patients with Parkinson's disease (PD) suffer from depression, which in many cases is more disabling than the impairment of motor function. Since the original discovery by Oleh...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.